We are interested in the development of bioactive molecules that can be used to treat infectious or inflammatory diseases. Our major target diseases include polymicrobial sepsis, rheumatoid arthritis, inflammatory bowel disease, and colon cancer. To generate useful target molecules that can be used to develop therapeutic agents against these infectious or inflammatory diseases, we are focusing on several chemoattractant G-protein coupled receptors (GPCRs). Since leukocyte trafficking in vivo is a crucial event that modulate immune and inflammatory responses, and chemotactic GPCRs mediate these response, the receptors can be considered as important primary targets to control infectious or inflammatory disorders. Currently, we are testing the effects and mechanism of action of chemotactic GPCR ligands against these diseases in experimental animal models.
Education
(PhD) 2000 Dept. of Life Science, POSTECH
Experience
2014 - Present Professor, Dept. of Biological Sciences, Sungkyunkwan University
2010 - 2014 Associate Professor, Dept. of Biological Sciences, Sungkyunkwan Universit
2008 - 2009 Visiting Associate Professor, Stanford University School of Medicine
2002 - 2010 Full-time Instructor, Assistant Professor, Associate Professor, Dong-A University College of Medicine
2000 - 2002 Postdoc, POSTECH
2015 - 2016 Chief of academic affair, Korean Peptide Protein Society
2014 - Senior Editorial Board Member, American Journal of Clinical and Experimental Immunology
2015 - Editorial Board Member, International Journal of Cancer Immunology & Immunotherapy
Journal Articles
(2023)
Sphingosylphosphorylcholine inhibits plasma cell differentiation and ameliorates experimental autoimmune encephalomyelitis.
FRONTIERS IN IMMUNOLOGY.
14,
2023
(2023)
Functional roles of sphingolipids in immunity and their implication in disease.
EXPERIMENTAL AND MOLECULAR MEDICINE.
55,
6
(2022)
Unique characteristics of lung-resident neutrophils are maintained by PGE(2)/PKA/Tgm2-mediated signaling.
BLOOD.
140,
8
(2022)
Targeting PLD2 in adipocytes augments adaptive thermogenesis by improving mitochondrial quality and quantity in mice.
JOURNAL OF EXPERIMENTAL MEDICINE.
219,
2
(2021)
Serum amyloid A promotes emphysema by triggering the reciprocal activation of neutrophils and ILC3s.
CLINICAL AND TRANSLATIONAL MEDICINE.
11,
12
(2021)
Activation of formyl peptide receptor 1 elicits therapeutic effects against collagen-induced arthritis.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.
25,
18
(2021)
Isovaleric acid ameliorates ovariectomy-induced osteoporosis by inhibiting osteoclast differentiation.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.
25,
9
(2021)
Sphingosylphosphorylcholine blocks ovariectomy-induced bone loss by suppressing Ca2+/calmodulin-mediated osteoclast differentiation.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.
25,
1
(2020)
Novel Sca-1(+) macrophages modulate the pathogenic progress of endotoxemia.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.
533,
1
(2020)
Formyl peptide receptors in the mucosal immune system.
EXPERIMENTAL AND MOLECULAR MEDICINE.
52,
10
(2020)
A membrane-tethering pepducin derived from formyl peptide receptor 3 shows strong therapeutic effects against sepsis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.
524,
1
(2019)
A phospholipase D2 inhibitor, CAY10594, ameliorates acetaminophen-induced acute liver injury by regulating the phosphorylated-GSK-3 beta/JNK axis.
SCIENTIFIC REPORTS.
9,
1
(2018)
A novel antimicrobial peptide acting via formyl peptide receptor 2 shows therapeutic effects against rheumatoid arthritis.
SCIENTIFIC REPORTS.
8,
(2018)
Activation of formyl peptide receptor 2 by WKYMVm enhances emergency granulopoiesis through phospholipase C activity.
BMB REPORTS.
51,
8
(2018)
Intracellular formyl peptide receptor regulates naive CD4 T cell migration.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.
497,
1
(2017)
A novel antimicrobial peptide isolated from centipede Scolopendra subspinipes mutilans stimulates neutrophil activity through formyl peptide receptor 2.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.
494,
1-2
(2017)
Lysophosphatidic acid protects against acetaminophen-induced acute liver injury.
EXPERIMENTAL AND MOLECULAR MEDICINE.
49,
(2017)
FAM19A5, a brain-specific chemokine, inhibits RANKL-induced osteoclast formation through formyl peptide receptor 2.
SCIENTIFIC REPORTS.
7,
Patent/Intellectual Property
펩타이드를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 약학적 조성물.
10-2016-0121335.
20170601.
KOREA, REPUBLIC OF
인간 호중구 세포의 활성을 조절하는 신규한 펩타이드.
10-2011-0119149.
20170215.
KOREA, REPUBLIC OF
마늘 유래의 신규 화합물 및 이를 포함하는 염증성 질환 치료용 조성물.
10-2015-0120713.
20170202.
KOREA, REPUBLIC OF
PHARCEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR INFECTIOUS DISEASES, CONTAINING M-3M3FBS, WHICH IS ACTIVATOR OF PHOSPHOLIPASE C, AS ACTIVE INGREDIENT.
2014/0005271.
20161018.
UNITED STATES
포스포리파제 D2 억제제를 유효성분으로 포함하는 박테리아 감염 질환 예방 또는 치료용 조성물.
10-2015-0032318.
20160805.
KOREA, REPUBLIC OF
COMPOSITION CONTAINING PEPTIDE LIGAND THAT BONDS WITH CXCR2 FOR TREATING INFECTIVE AND INFLAMMATORY DISEASES.
13/880,889.
20150120.
UNITED STATES
혈청 아밀로이드 A 생성 저해제 또는 포밀펩타이드 수용체 2 활성 조절제를 포함하는 거품세포 형성 억제용 약학적 조성물.
10-2012-0090484.
20141112.
KOREA, REPUBLIC OF
WKYMVm 펩티드를 함유하는 염증성 장질환 예방 또는 치료용 약학적 조성물.
10-2012-0090978.
20140811.
KOREA, REPUBLIC OF
알파-이소-쿠베베놀을 유효성분으로 포함하는 감염성 및 염증성 질환의 예방 또는 치료용 조성.
10-2012-0094114.
20140709.
KOREA, REPUBLIC OF
알파-이소-쿠베벤을 유효성분으로 포함하는 감염성 및 염증성 질환의 예방 또는 치료용 조성물.
10-2012-0089750.
20140709.
KOREA, REPUBLIC OF
펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물.
10-2011-0142340.
20140204.
KOREA, REPUBLIC OF
펩타이드, 5-플루오루우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물.
10-2011-0142340.
20140204.
KOREA, REPUBLIC OF
스매드6번 (smad6)으로부터 유래된 펩타이드를 유효성분으로 포함하는 패혈증 또는 패혈성.
10-2011-0144262.
20140129.
KOREA, REPUBLIC OF
포스포리파제Ｃ의 활성인자인 ｍ－３Ｍ３ＦＢＳ를 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 약학적 조성물.
10-2011-0024239.
20130829.
KOREA, REPUBLIC OF
ＣＸＣＲ２에 결합하는 펩타이드 리간드를 포함하는 감염성 및 염증성 질환 치료용 조성물.
10-2010-0103259
.
20130320.
KOREA, REPUBLIC OF
면역 조절 리간드.
10-2010-0047982.
20120813.
KOREA, REPUBLIC OF
Immune-modulating peptide.
12/246,229.
20110913.
UNITED STATES
오미자로부터 추출한 alpha-iso-cubebene 화합물을 유효성분으로 함유하는 항염증 질환에 대한 예방 및 치료제.
10-2008-0053169.
20101027.
KOREA, REPUBLIC OF
Honors / Awards
Several patents on therapeutic agents against sepsis or rheumatoid arthritis
Conference Paper
(2020)
Identification of novel Sca-1+ macrophages generated from lipopolysaccharide-induced sepsis model.
2020 KAI International Meeting.
KOREA, REPUBLIC OF
(2020)
New Gr-1+ myeloid cells driving mortality in bacterial infection.
KSBMB International Conference 2020.
KOREA, REPUBLIC OF
(2020)
A branched-chain fatty acid ameliorates ovariectomy-induced osteoporosis by inhibiting osteoclast differentiation.
KSBMB International Conference 2020.
KOREA, REPUBLIC OF
(2020)
Blockage of ovariectomy-induced bone loss via suppressing Ca2+/calmodulin-mediated osteoclast differentiation by a sphingolipid.
KSBMB International Conference 2020.
KOREA, REPUBLIC OF
(2019)
A novel Gr-1+ myeloid population that plays an essential role in mortality during bacterial infection.
2019 KAI International Meeting.
KOREA, REPUBLIC OF
(2019)
A membrane-tethering pepducin derived from formyl peptide receptor 3 shows strong therapeutic effects against sepsis.
KSBMB International Conference 2019.
KOREA, REPUBLIC OF
(2019)
An immune-modulating peptide WKYMVm shows therapeutic effect against rheumatoid arthritis by inhibiting dendritic cell-dependent Th1 and Th17 differentiation through formyl peptide receptor 1.
KSBMB International Conference 2019.
KOREA, REPUBLIC OF
(2019)
Therapeutic effects of a lipid molecule on autoimmune arthritis by upregulating and sustaining identity of regulatory T cells.
KSBMB International Conference 2019.
KOREA, REPUBLIC OF
(2019)
Therapeutic effects of a phospholipase D1 inhibitor against polymicrobial sepsis.
Immunology 2019.
UNITED STATES
(2019)
A novel inflammasome inhibitor that blocks caspase-1 activity.
2019 KAI International Meeting.
KOREA, REPUBLIC OF
(2018)
An immune-modulating peptide WKYMVm promotes emergency granulopoiesis through formyl peptide receptor 2.
KAI International Meeting 2018.
KOREA, REPUBLIC OF
(2018)
Therapeutic effects of a novel FPR2 ligand against rheumatoid arthritis.
KAI International Meeting 2018.
KOREA, REPUBLIC OF
(2018)
Lysophosphatidic acid strongly protects acute liver injury caused by acetaminophen in an experimental animal model.
Immunology 2018.
UNITED STATES
(2017)
Dendritic cell differentiation is inhibited by serum amyloid A through Toll-like receptor 2 and formyl peptide receptor 2.
2017 KAI International Meeting.
KOREA, REPUBLIC OF
(2017)
Identification of a novel antimicrobial peptide that stimulates neutrophil activity through formyl peptide receptor 2.
2017 KAI International Meeting.
KOREA, REPUBLIC OF
(2017)
A brain-specific chemokine, FAM19A5, inhibits RANKL-induced osteoclast formation.
Immunology 2017.
UNITED STATES
(2017)
Suppression of foreign body giant cell formation by phospholipase Cγ1 via RUNX1/PU.1/ DC-STAMP axis in macrophages.
Immunology 2017.
UNITED STATES
(2016)
Bioactive lipid A attenuates symptoms of rheumatoid arthritis enhancing stability of regulatory T cells.
2016 KAI-IBS Joint International Conference.
KOREA, REPUBLIC OF
(2016)
Functional role of phospholipase D2 on the acetaminophen-induced acute liver injury.
2016 KAI-IBS Joint International Conference.
KOREA, REPUBLIC OF
(2016)
Phosoholipase D2 as a target to control polymicrobial sepssis.
International Meeting of the Federation of Korean Microbiooligcal Societies.
KOREA, REPUBLIC OF
